DARE - Daré Bioscience, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
0.9148
+0.0148 (+1.65%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close0.9000
Open1.0100
Bid0.0000 x 900
Ask0.0000 x 3000
Day's Range0.8700 - 1.1200
52 Week Range0.6000 - 3.2500
Volume9,626,027
Avg. Volume1,352,126
Market Cap15.262M
Beta (3Y Monthly)2.68
PE Ratio (TTM)N/A
EPS (TTM)-1.0620
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.50
Trade prices are not sourced from all markets
  • GlobeNewswire18 hours ago

    Daré Bioscience, Inc. Announces Positive Results in Thermography Feasibility Study with Sildenafil Cream, 3.6%, a Potential Therapy for Female Sexual Arousal Disorder

    Daré Bioscience, Inc. (DARE), a leader in women’s health innovation, today announced positive findings from an investigational study designed to evaluate the feasibility of using thermography technology to assess the pharmacodynamics of Sildenafil Cream, 3.6% (Sildenafil Cream) in normal healthy women. Sildenafil is the active ingredient in a tablet for oral administration marketed under the brand name Viagra®, which is indicated for the treatment of erectile dysfunction (ED) in men. Daré Bioscience, in collaboration with Strategic Science & Technologies, LLC (SST), is developing Sildenafil Cream as a potential treatment for female sexual arousal disorder (FSAD), a condition analogous to ED in men.  Sildenafil Cream is a topically administered formulation of sildenafil designed to increase local blood flow and provide a potential improvement in genital arousal response and overall sexual experience for women.

  • GlobeNewswire20 days ago

    Daré Bioscience to Present at the 2019 BIO International Convention

    Daré Bioscience, Inc. (DARE), a leader in women’s health innovation, today announced that Sabrina Johnson, President and Chief Executive Officer, will present at the 2019 BIO International Convention on Tuesday, June 4, 2019, starting at 11:15 a.m. Eastern Time in Philadelphia, PA. The BIO International Convention brings together the global biotechnology and pharmaceutical industry and is expected to include over 500 education sessions and networking opportunities with 16,000+ attendees from 67 countries. The theme for the 2019 BIO International Convention is “It Starts with One,” to highlight the critical daily contributions that combine to bring new breakthroughs to the world, and the women and men who bring new ideas and perspectives to the forefront.

  • Zacks Small Cap Research21 days ago

    DARE: Several Important Milestones, Including Ovaprene PCT Read-Out, Anticipated Later This Year

    R&D expense, including license fees, was $1.8M, compared to $1.2M and $1.9M in the prior-year and three-month periods, respectively.  We note that Q1 expenses included $113k accrual associated with the license fees related to DARE-BV1, DARE’s new bacterial vaginosis candidate.  The year-earlier period did not include any license-related expenses while the quarter-earlier period did include $275k in license fees.

  • Thomson Reuters StreetEvents21 days ago

    Edited Transcript of DARE earnings conference call or presentation 14-May-19 8:30pm GMT

    Q1 2019 Dare Bioscience Inc Earnings Call

  • GlobeNewswirelast month

    Daré Bioscience Reports First Quarter 2019 Financial Results and Company Update

    Daré Bioscience, Inc. (DARE), a leader in women’s health innovation, today reported financial results for the first quarter ended March 31, 2019 and provided a Company update. “We believe our differentiated product candidate portfolio is well poised to drive value in 2019 and 2020 as we seek to execute against clinical and regulatory milestones, particularly with our Phase 3 and Phase 2 candidates. During the first quarter, we continued enrollment in the postcoital test clinical trial of Ovaprene, our monthly, non-hormonal contraceptive candidate, and we remain on track to report top-line data in the second half of 2019.

  • GlobeNewswirelast month

    Daré Bioscience Announces the Publication of a Pharmacokinetics Study of DARE-FRT1, a Potential Therapy for Preterm Birth and Fertility, in Drug Delivery and Translational Research

    Daré Bioscience, Inc. (DARE), a leader in women’s health innovation, today announced the article entitled “Pharmacokinetics and tolerability of a novel progesterone intravaginal ring in sheep” was published online in the journal Drug Delivery and Translational Research. The goal of the research was to characterize the in vitro release, pharmacokinetics and local tolerability of DARE-FRT1, a novel ethylene-vinyl acetate intravaginal ring (IVR) drug delivery technology delivering progesterone, in drug-naïve ovariectomized female Dorset crossbred sheep. DARE-FRT1 is being developed as an optimized IVR technology capable of delivering bio-identical progesterone hormone for the prevention of preterm birth (PTB), and for pregnancy maintenance and support as part of an assistive reproductive technology (ART) procedure.  DARE-FRT1 is designed to allow for convenient non-invasive, non-oral administration of bio-identical progesterone over a 14-day period.

  • GlobeNewswirelast month

    Daré Bioscience to Host First Quarter 2019 Financial Results and Company Update Conference Call and Webcast

    SAN DIEGO, May 07, 2019 -- Daré Bioscience, Inc.(NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of DARE earnings conference call or presentation 4-Apr-19 12:30pm GMT

    Q4 2018 Dare Bioscience Inc Earnings Call

  • GlobeNewswire2 months ago

    Dr. James Simon, Award-Winning Physician, Presents on Ovaprene® as a Promising Novel Non-Hormonal Contraceptive Method in Clinical Development

    Daré Bioscience, Inc. (DARE), a leader in women’s health innovation, today announced Ovaprene’s inclusion in a presentation to physicians on the latest forms of novel contraception. Ovaprene is Daré’s clinical stage, non-hormonal vaginal ring designed to provide multiple weeks of contraceptive protection. The presentation entitled, “Contraception 2019: What about LARC, Rings, Gel, even Apps?”, was given by noted physician and women’s health expert Dr. James A. Simon during the Survival Skills for Today’s Gynecologist continuing medical education conference in New York City on Sunday, April 14th.

  • Zacks Small Cap Research2 months ago

    DARE: Pipeline Timelines Intact. Several Development-Related Milestones Upcoming

    By Brian Marckx, CFA NASDAQ:DARE READ THE FULL DARE RESEARCH REPORT Q4 / Pipeline Update Daré Bioscience (NASDAQ:DARE) reported financial results for their fourth quarter and provided an operational update. ...

  • GlobeNewswire2 months ago

    Daré Bioscience, Inc. Prices Underwritten Public Offering of Common Stock

    Daré Bioscience, Inc. (DARE), today announced the pricing of an underwritten public offering of 4,575,000 shares of its common stock at a price of $1.10 per share. After the underwriting discount and estimated offering expenses payable by the company, the company expects to receive net proceeds of approximately $4.4 million, assuming no exercise of the overallotment option, and approximately $5.1 million assuming the overallotment option is exercised in full. Roth Capital Partners is acting as the sole book-runner for the offering.

  • GlobeNewswire2 months ago

    Daré Bioscience, Inc. Announces Proposed Public Offering of Common Stock

    Daré Bioscience, Inc. (DARE), a leader in women’s health innovation, today announced that it intends to offer shares of its common stock in an underwritten public offering.  Daré expects to grant to the underwriters of the offering a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the underwritten public offering on the same terms and conditions.

  • GlobeNewswire2 months ago

    Daré Bioscience Announces Publication of Pharmacokinetics Study of DARE-HRT1, a Potential Hormone Replacement Therapy, in the Journal of Pharmaceutical Sciences

    Daré Bioscience, Inc. (DARE), a leader in women’s health innovation, today announced the article entitled “Pharmacokinetics and tolerability of a novel 17β-estradiol and progesterone intravaginal ring in sheep” was published online in the Journal of Pharmaceutical Sciences (JPharmSci®). The goal of the research described in the article was to characterize the release, pharmacokinetics and local tolerability of DARE-HRT1, a potential and novel hormone replacement therapy.  DARE-HRT1, an ethylene-vinyl acetate (EVA) intravaginal ring (IVR) drug delivery technology delivering 17β-estradiol (E2) and progesterone (P), was evaluated in drug-naïve ovariectomized female Dorset crossbred sheep. DARE-HRT1 is being developed as a combination bio-identical estradiol and bio-identical progesterone IVR for hormone replacement therapy (HRT) to treat vasomotor symptoms (VMS), commonly called hot-flashes and associated with menopause, as part of an HRT regimen.

  • GlobeNewswire3 months ago

    Daré Bioscience, Inc. Regains Listing Compliance on Nasdaq

    SAN DIEGO, April 01, 2019 -- Daré Bioscience, Inc.(NASDAQ: DARE), a leader in women’s health innovation, today announced that it received notice from The Nasdaq Stock Market.

  • GlobeNewswire3 months ago

    Daré Bioscience, Inc. to Host Business Update and Full Year 2018 Financial Results Conference Call and Webcast

    SAN DIEGO, April 01, 2019 -- Daré Bioscience, Inc.(NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast.

  • GlobeNewswire3 months ago

    World-renowned Scientist, Described as the Edison of Medicine by Forbes Magazine, Dr. Robert Langer Joins Daré Bioscience Scientific Advisory Board

    Daré Bioscience, Inc. (DARE), a leader in women’s health innovation, announced that Dr. Robert Langer, co-inventor of Daré‘s novel, segmented intravaginal ring (IVR) drug delivery technology and one of the 10 Institute Professors at the Massachusetts Institute of Technology (MIT) joined the company’s Scientific Advisory Board.

  • ACCESSWIRE3 months ago

    Four Healthcare Stocks Heating Up On Monday

    Whereas other sectors may cut corners or decrease quality in the name of revenue, healthcare companies do not have this luxury. As consumers, we expect the healthcare industry to create products and treatments to help us feel better and to invest in future technologies so that medical professionals can assist their patients in preventive medicine, not just reactive care. The healthcare industry has demonstrated in the first few months of 2019 that these expectations are more than fair, and if companies in the sector continue to prove their aptitude for helping patients, this may catalyze investor interest in the future.

  • GlobeNewswire3 months ago

    Daré Bioscience, Inc. to Present at the 31st Annual ROTH Conference

    SAN DIEGO, March 18, 2019 -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Johnson, President and Chief Executive.

  • GlobeNewswire3 months ago

    Daré Bioscience Announces Publication of Positive Clinical Findings for Vaginal Administration of Tamoxifen for the Treatment of VVA

    Daré Bioscience, Inc. (DARE), a leader in women’s health innovation, today announced the publication of clinical findings for vaginally-administered tamoxifen in Clinical and Experimental Obstetrics and Gynecology, a leading international journal for publication of research focused on the development of new therapeutic interventions for obstetrics and gynecology. Daré’s product candidate, DARE-VVA1, incorporates tamoxifen in a proprietary formulation designed for vaginal delivery. Daré holds the exclusive worldwide rights to patents issued in the U.S. and Japan covering the use and delivery of DARE-VVA1 for vulvar and vaginal atrophy (VVA) and a U.S. patent covering composition, use and delivery of DARE-VVA1 for VVA.

  • GlobeNewswire3 months ago

    Daré Bioscience receives notification of second award from the National Institutes of Health Eunice Kennedy Shriver National Institute of Child Health and Human Development for the development of Ovaprene®

    Daré Bioscience, Inc. (DARE), a leader in women’s health innovation, today announced that it received a second Notice of Award of $982,851, part of a grant providing up to $1.9 million in the aggregate for Ovaprene® research from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), a division of the National Institutes of Health (NIH). This second award, an additional $982,851, followed the NIH’s review of an interim data analysis and other results of the first phase of work. The award will be applied to important clinical development efforts supporting Ovaprene, a potential first-in-class hormone-free contraceptive solution.

  • GlobeNewswire3 months ago

    Daré Bioscience, Inc. to Present at the Cowen 39th Annual Healthcare Conference

    SAN DIEGO, March 05, 2019 -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Johnson, President and Chief Executive.

  • GlobeNewswire4 months ago

    Daré Bioscience, Inc. to Present at the 16th Annual BIO Asia International Conference

    Daré Bioscience, Inc. (DARE), a leader in women’s health innovation, today announced that Sabrina Johnson, President and Chief Executive Officer, will present at the 16th Annual BIO Asia International Conference on Tuesday, March 5, 2019 at 4:15 p.m. Japanese Standard Time in Tokyo, Japan. The BIO Asia International Conference brings together the global biotechnology and pharmaceutical industry to explore licensing collaborations and investor engagement in the current Asia-Pacific business and policy environments.  “Given our focus on identifying development and global commercialization partners for our portfolio of women’s health product candidates, we are pleased to have the opportunity to present and participate in the partnering meetings organized by the conference,” said Sabrina Johnson.

  • GlobeNewswire4 months ago

    Daré Bioscience, Inc. to Present at the 2019 BIO CEO & Investor Conference

    SAN DIEGO, Feb. 05, 2019 -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Johnson, President and Chief Executive.

  • GlobeNewswire5 months ago

    Daré Bioscience Provides Update for Investors on Development Programs and Anticipated 2019 Milestones

    Daré Bioscience, Inc. (DARE), a leader in clinical-stage women’s health innovation, today provided an update on its product portfolio for investors that includes anticipated 2019 clinical milestones. “2018 was a year of substantial execution as we assembled a broad and differentiated pipeline of product candidates across women’s health,” stated Sabrina Martucci Johnson, President and Chief Executive Officer of Daré.